인벤티지랩
25,100KRWMarket close of 10/20 (Tue)
Down -0.20%-50KRWMarket close of 10/20 (Tue)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)26,200KRWUp +4.38%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 25,450
- High
- 25,950
- Low
- 24,100
- Day range
- Day range low 24,100 high 25,950, open 25,450, close 25,100, previous close 25,150
- Volume
- 6×10K shares
- 1.4B KRW 0.39× the 20-session average
Market close of 10/20 (Tue)
Where it sits in the 1-year range
2%1-year close range 23,350 to 99,500 won, 2% up from the low
2% of the way up from the lowest close in 1 year (252 sessions) · -74.8% from the high
Something to check
1 to check: operating loss
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsto check-33.6B KRWOperating income over the last four quarters -33.6B KRW (loss)
- Daily moveusual range-0.20%-0.20%, 0.0× the usual (20-session average ±5.40%)That day -0.20% · usual ±5.40% · large-move threshold ±10.8%
- Trading valueusual range0.4×1.4B KRW, 0.4× the 20-session average0.39× the 20-session average · check threshold 3×
The other 3 are within the usual range
- Recent filings0Last 14 days
- Foreign & institutional+400.00 million KRWusual range
- Data date10/20 (Tue)Market close
See the full check report
Same sector · 바이오 R&D
Down -2.19%· 16 of 64 stocks up, preferred shares excluded · trading value 190.5B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -9.6% | Down -3.35% | 51.1B KRW |
| 올릭스 | Close over the last 20 sessions -12.2% | Down -4.03% | 19.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -11.8% | Down -1.93% | 15.1B KRW |
| 리가켐바이오 | Close over the last 20 sessions -15.4% | Down -1.41% | 12.1B KRW |
| 프로티나 | Close over the last 20 sessions +31.8% | Up +7.38% | 10.0B KRW |
Schedule
- Q3 report due · 11/16 (Mon) · in 25 days
- Next data 10/22 (Thu) after 08:50
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.